Effects of the traditional Chinese herb Astragalus membranaceus in patients with poststroke fatigue: A double-blind, randomized, controlled preliminary study

详细信息    查看全文

• 作者：Chung-Hsiang Liu^a ; ^b ; ^{greengen@gmail.com} ; Chang-Hai Tsai^c ; ^d ; ^{chchai@mail.cmuh.org.tw} ; Tsai-Chung Li^e ; ^{tcli@mail.cmu.edu.tw} ; Yu-Wan Yang^b ; ^{d6136@mail.cmuh.org.tw} ; Wei-Shih Huang^b ; ^{d2742@mail.cmuh.org.tw} ; Ming-Kui Lu^b ; ^{d4297@mail.cmuh.org.tw} ; Chun-Hung Tseng^b ; ^{d8333@mail.cmuh.org.tw} ; Hui-Chun Huang^b ; ^{d12483@mail.cmuh.org.tw} ; Kuan-Fei Chen^b ; ^{d11866@mail.cmuh.org.tw} ; Thih-Shan Hsu^b ; ^{d12712@mail.cmuh.org.tw} ; Yi-Ting Hsu^b ; ^{d11835@mail.cmuh.org.tw} ; Chon-Haw Tsai^b ; ^c ; ^{d8079@mail.cmuh.org.tw} ; Ching-Liang Hsieh^a ; ^f ; ^g ; ^{clhsieh@mail.cmuh.org.tw}
• 关键词：Astragalus membranaceus ; Clinical trial ; Poststroke fatigue ; EORTC QLQ-C30 scores ; BFI scores ; SF-36 scores
• 刊名：Journal of Ethnopharmacology
• 出版年：2016
• 出版时间：24 December 2016
• 年：2016
• 卷：194
• 期：Complete
• 页码：954-962
• 全文大小：431 K
• 卷排序：194

文摘

Astragalus membranaceus (AM) is the first-choice herb for fatigue treatment in traditional Chinese medicine and the main herb used for stroke treatment in China and Taiwan. The purpose of this study was to evaluate the effect of AM on poststroke fatigue (PSF).Materials and methodsThis study was designed as a double-blind, randomized, controlled preliminary study. Sixty-four patients with PSF were assigned to treatment group (TG; 31 patients), which received oral administration of AM (2.8 g three times per day) for 28 days, and a control group (CG; 33 patients), which received a placebo. The primary outcome measures were the changes in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and Brief Fatigue Index (BFI) scoresResultsA total of 61 patients (29 patients in the TG and 32 patients in the CG) completed the trial. The difference in BFI scores between Visit 2 and Visit 1 was –17.83±17.70 in the TG, which was greater than that in the CG (–8.03±9.95; p=0.01); additionally, the difference in BFI scores between Visit 3 and Visit 1 was –16.48±16.41 in the TG, which was also greater than that in the CG (–9.47±13.39; p=0.05). In the EORTC QLQ-C30, the difference in cognitive functioning scores between Visit 2 and Visit 1 was 14.37±13.89 in the TG, which was greater than that in the CG (3.65±19.74; p=0.02); additionally, the difference in these scores between Visit 3 and Visit 1 was 14.37±16.50 in the TG, which again was greater than that in the CG (6.25±19.74; p=0.04). The difference in social functioning scores between Visit 3 and Visit 1 was 9.77±15.12 in the TG, which was greater than that in the CG (–1.56±20.46; p=0.01). The difference in global quality of life (QOL) scores between Visit 2 and Visit 1 was 14.08±18.78 in the TG, which was also greater than that in the CG (1.56±18.14; p=0.003); moreover, the difference in these scores between Visit 3 and Visit 1 was 10.92±17.55 in the TG, and this was greater than that in the CG (1.82±15.8; p=0.05).ConclusionAM can improve BFI scores; cognitive functioning, social functioning, and global QOL scores in the EORTC QLQ-C30. Our results suggest that physicians should pay close attention to the unmet medical needs of patients with PSF. AM is helpful for treating patients with PSF; however, additional studies with a larger sample and a longer period of investigation are required.